Feed HUMDF
Summary
63 / 100 · Bulios Score
Valuation 83Growth 100Profitability 40Quality 49Debt 69Stability 28
What speaks for it
- Out of every 100 CNY of revenue, 224 CNY is left as net profit.
- Revenue grew by 201% a year over the last 3 years.
- It holds more cash than debt: ¥1.07B against ¥354.3M.
- The share price is below the Bulios Fair Price.
What to watch
- It reports a profit, yet spends more cash than it brings in.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price
Current price $0.3
Drug Manufacturers - Specialty & Generic industry median
P/E today 1.9
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 1.9 CNY for 1 CNY of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (CNY)
2021202220232024202520262027
Diluted EPS (CNY)
2021202220232024202520262027
- Analyst estimate
Revenue grew by 123% a year over 5 years. Over the last 3 years it grew by 201% a year.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesCash and short-term investments ¥1.07B
Debt ¥354.3M
It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.